University of Chicago

University of Chicago, AbbVie sign cancer research deal

University of Chicago, AbbVie sign cancer research deal

Leukemia patients got a ray of hope last week when the U.S. Food and Drug Administration approved a new drug that targets a subset of leukemia patients with a genetic abnormality that makes the cancer harder to treat.

Venclexta, which could help up to 1,500 patients a year in their fight against cancer, was developed in part by North Chicago-based AbbVie — but is based on research done 25 years ago at the University of Chicago.

Now a new collaboration between the pharmaceutical giant and the Hyde Park school aims to repeat that success, and to shrink the timeline between cutting-edge academic research and patients getting their hands on useful drugs.

Under the...

56°